Keyphrases
Skeletal muscle
100%
Whole-body
100%
Volumetric muscle Loss
100%
FDA-approved Drugs
100%
Metabolic Effects
100%
Loss Model
100%
Pathophysiology
50%
Formoterol
50%
C57BL
33%
Nintedanib
33%
Adult Male
33%
Leucine
33%
Muscle Strength
33%
Regeneration
16%
Skeletal muscle Mass
16%
Antifibrotic
16%
High Dose
16%
Functional Impairment
16%
Treatment Duration
16%
Lipid Peroxidation
16%
Muscle Regeneration
16%
Ultra-low Dose
16%
Myogenic
16%
Large Animal Model
16%
Myofiber
16%
Cross-sectional Area
16%
Muscle Mass
16%
Dosage Effect
16%
Metabolic Rate
16%
Blood Lipids
16%
Muscle Tissue
16%
Tolerated Dose
16%
Whole-body Metabolism
16%
Skeletal muscle Myofiber
16%
Medicine and Dentistry
Pathophysiology
100%
Formoterol
100%
Skeletal Muscle
100%
Nintedanib
66%
Muscle Strength
66%
Leucine
66%
Low Drug Dose
33%
Injury
33%
Drug Megadose
33%
Muscle Regeneration
33%
Functional Disease
33%
Body Fat
33%
Promoter Region
33%
Metabolic Rate
33%
Lipid Oxidation
33%
Muscle Tissue
33%
Drug
33%
Biochemistry, Genetics and Molecular Biology
Skeletal Muscle
100%
Formoterol
100%
Leucine
66%
C57BL 6 Mouse
66%
Muscle Strength
66%
Animal Models
33%
Metabolic Pathway
33%
Lipid Oxidation
33%
Scale up
33%
Muscle Regeneration
33%
Body Fat
33%
Promoter Region
33%
Drug Megadose
33%
Low Drug Dose
33%
Metabolic Rate
33%
Agricultural and Biological Sciences
Leucine
100%
Mouse
100%
Muscle Strength
100%
Skeletal Muscle
100%
Muscle Tissue
50%
Body Fat
50%
Neuroscience
Formoterol
100%
Skeletal Muscle
100%
Leucine
66%
Nintedanib
66%
Promoter Region
33%
Metabolic Pathway
33%